Cuprina Secures Exclusive Rights to Southeast Asia’s First UNIDO/GEF- Demonstrated Medical Waste Recycling Technology
Rhea-AI Summary
Cuprina Holdings (Nasdaq: CUPR) has secured exclusive licensing rights to Southeast Asia's first UNIDO/GEF-demonstrated medical waste recycling technology. The technology, licensed from Zhejiang Heliang Technology, uses advanced high-temperature steam treatment to sterilize and recycle medical waste into high-value resins, particularly focusing on plastic-based materials.
The license covers Singapore with expansion options to 10 additional Southeast Asian countries. The technology offers an environmentally friendly alternative to traditional incineration methods, supported by extensive regulatory approvals and ISO certifications (9001, 14001, 45001). Singapore's biohazardous medical waste increased from 4,400 tons in 2016 to 5,700 tons in 2020, growing approximately 5% annually.
The global medical waste management market is projected to grow from $34.06 billion in 2023 to $59.42 billion by 2030, with Asia-Pacific as the fastest-growing region.
Positive
- Exclusive licensing rights for an environmentally friendly medical waste recycling technology in Singapore
- Option to expand into 10 additional Southeast Asian countries
- Technology validated over two decades with ISO certifications and regulatory approvals
- Targeting fast-growing market projected to reach $59.42B by 2030
- Addresses growing medical waste problem in Singapore (5% annual growth)
Negative
- Still needs to obtain operating licenses in Singapore
- Requires construction of new facility with associated costs
- Integration with existing waste management framework pending
News Market Reaction
On the day this news was published, CUPR gained 12.23%, reflecting a significant positive market reaction. Argus tracked a peak move of +742.4% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $49M at that time. Trading volume was exceptionally heavy at 20.2x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
SINGAPORE, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced it has secured exclusive licensing rights to Southeast Asia’s first medical waste recycling technology developed under the oversight of the United Nations Industrial Development Organization (UNIDO) and the Global Environment Facility (GEF), the major alliance supporting developing countries in achieving global environmental benefits.
The license, signed by Cuprina with China-based Zhejiang Heliang Technology Co., Ltd., covers Singapore and an option to expand into ten additional Southeast Asian countries.
As opposed to current medical waste technologies which incinerate waste and send its ash to landfills – a method that releases toxic emissions and strains Singapore’s already limited landfill capacity – the new technology uses advanced high-temperature steam treatment to sterilize and decontaminate medical waste, particularly plastic-based materials. Once clean, these materials are sorted and recycled into high-value resins and converted into sustainable raw materials that re-enter the economy.
The technology has gained validation over two decades via collaboration between Chinese authorities, UNIDO, and GEF, as well as via ISO certifications (9001, 14001, 45001) and extensive regulatory approvals.
Cuprina intends to apply for the operating licenses required in Singapore to construct a facility for the new technology, and is also engaging with the nation’s leading toxic waste disposal companies to integrate these processes seamlessly into the national waste management framework.
By establishing Singapore as the first hub for the technology outside of China, Cuprina aims to capture significant growth opportunities across Southeast Asia, where many governments are tightening environmental standards.
In Singapore, biohazardous medical waste increased from 4,400 tons in 2016 to 5,700 tons in 2020, an average annual increase of around
According to a recent study by Grand View Research, the global medical waste management market was valued at USD 34.06 billion in 2023 and is projected to reach USD 59.42 billion by 2030, growing at
“This isn’t just about new equipment—it’s about bringing in a globally validated technology that has been refined, certified, and proven over two decades,” said Cuprina CEO David Quek Yong Qi. “By securing exclusive rights for Southeast Asia, Cuprina expects to lead the transition from incineration and landfill toward a new model that protects public health, safeguards the environment, and creates long-term value for our shareholders.”
About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards.
For more information, please visit https://cuprina.com/
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com
FAQ
What exclusive rights did Cuprina (CUPR) secure for medical waste recycling?
How does Cuprina's new medical waste recycling technology work?
What is the market size for medical waste management that Cuprina (CUPR) is targeting?
How much medical waste does Singapore currently produce?
What regulatory approvals does Cuprina need for the medical waste technology?
